{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:17:51Z","timestamp":1788675471504,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,19]]},"DOI":"10.7759\/cureus.99645","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:57:05Z","timestamp":1766170625000},"source":"Crossref","is-referenced-by-count":1,"title":["Progressive Weakness in Adulthood: Lipid Storage Myopathy With Suspected Sertraline-Associated Etiology"],"prefix":"10.7759","author":[{"given":"Jaclyn","family":"Feely","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Saliba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NdukeAbasi","family":"Nze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Specific fatty acid oxidation disorders","author":"Vockley J","year":"2025","unstructured":"Vockley J. Specific fatty acid oxidation disorders. UpToDate. 2025,","journal-title":"UpToDate"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000001182","article-title":"Metabolic myopathies","volume":"28","author":"Tarnopolsky MA","year":"2022","unstructured":"Tarnopolsky MA. Metabolic myopathies. Continuum (Minneap Minn). 2022, 28:1752-77. 10.1212\/CON.0000000000001182","journal-title":"Continuum (Minneap Minn)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.02.029","article-title":"Myotoxicity of statins: mechanism of action","volume":"175","author":"du Souich P","year":"2017","unstructured":"du Souich P, Roederer G, Dufour R. Myotoxicity of statins: mechanism of action. Pharmacol Ther. 2017, 175:1-16. 10.1016\/j.pharmthera.2017.02.029","journal-title":"Pharmacol Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09568-3","article-title":"Clinical manifestations and management of fatty acid oxidation disorders","volume":"21","author":"Merritt JL 2nd","year":"2020","unstructured":"Merritt JL 2nd, MacLeod E, Jurecka A, Hainline B. Clinical manifestations and management of fatty acid oxidation disorders. Rev Endocr Metab Disord. 2020, 21:479-93. 10.1007\/s11154-020-09568-3","journal-title":"Rev Endocr Metab Disord"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-024-02830-x","article-title":"Lipid storage myopathy associated with sertraline treatment is an acquired mitochondrial disorder with respiratory chain deficiency","volume":"148","author":"Hedberg-Oldfors C","year":"2024","unstructured":"Hedberg-Oldfors C, Lindgren U, Visuttijai K, et al.. Lipid storage myopathy associated with sertraline treatment is an acquired mitochondrial disorder with respiratory chain deficiency. Acta Neuropathol. 2024, 148:73. 10.1007\/s00401-024-02830-x","journal-title":"Acta Neuropathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-60204-8_5","article-title":"Fatty acid oxidation in peroxisomes: enzymology, metabolic crosstalk with other organelles and peroxisomal disorders","volume":"1299","author":"Wanders RJ","year":"2020","unstructured":"Wanders RJ, Vaz FM, Waterham HR, Ferdinandusse S. Fatty acid oxidation in peroxisomes: enzymology, metabolic crosstalk with other organelles and peroxisomal disorders. Adv Exp Med Biol. 2020, 1299:55-70. 10.1007\/978-3-030-60204-8_5","journal-title":"Adv Exp Med Biol"},{"key":"ref7","article-title":"Diagnostic approach to patients with suspected muscle disorders (myopathies)","author":"Liewluck T","year":"2025","unstructured":"Liewluck T. Diagnostic approach to patients with suspected muscle disorders (myopathies). UpToDate. 2025,","journal-title":"UpToDate"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.991060","article-title":"Lipid storage myopathy due to late-onset multiple acyl-CoA dehydrogenase deficiency with novel mutations in ETFDH: a case report","volume":"13","author":"Tian H","year":"2022","unstructured":"Tian H, Zhong Y, Liu Z, Wei L, Yuan Y, Zhang Y, Wang L. Lipid storage myopathy due to late-onset multiple acyl-CoA dehydrogenase deficiency with novel mutations in ETFDH: a case report. Front Neurol. 2022, 13:991060. 10.3389\/fneur.2022.991060","journal-title":"Front Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2023.11.001","article-title":"A clinical approach to diagnosis and management of mitochondrial myopathies","volume":"21","author":"Chin HL","year":"2024","unstructured":"Chin HL, Lai PS, Tay SK. A clinical approach to diagnosis and management of mitochondrial myopathies. Neurotherapeutics. 2024, 21:e00304. 10.1016\/j.neurot.2023.11.001","journal-title":"Neurotherapeutics"},{"key":"ref10","article-title":"Electrodiagnostic Evaluation of Myopathy","author":"Shanina E","year":"2025","unstructured":"Shanina E, Smith RG. Electrodiagnostic Evaluation of Myopathy. StatPearls Publishing, Treasure Island, USA; 2025."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4081\/ejtm.2022.10645","article-title":"Neutral lipid storage disease with myopathy: a 10-year follow-up case report","volume":"32","author":"Missaglia S","year":"2022","unstructured":"Missaglia S, Tavian D, Angelini C. Neutral lipid storage disease with myopathy: a 10-year follow-up case report. Eur J Transl Myol. 2022, 32:10.4081\/ejtm.2022.10645","journal-title":"Eur J Transl Myol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2016.07.001","article-title":"Fluoxetine and the mitochondria: a review of the toxicological aspects","volume":"258","author":"de Oliveira MR","year":"2016","unstructured":"de Oliveira MR. Fluoxetine and the mitochondria: a review of the toxicological aspects. Toxicol Lett. 2016, 258:185-91. 10.1016\/j.toxlet.2016.07.001","journal-title":"Toxicol Lett"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfs100","article-title":"Mitochondrial dysfunction induced by sertraline, an antidepressant agent","volume":"127","author":"Li Y","year":"2012","unstructured":"Li Y, Couch L, Higuchi M, Fang JL, Guo L. Mitochondrial dysfunction induced by sertraline, an antidepressant agent. Toxicol Sci. 2012, 127:582-91. 10.1093\/toxsci\/kfs100","journal-title":"Toxicol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/cells8080795","article-title":"Mitochondrial uncoupling: a key controller of biological processes in physiology and diseases","volume":"8","author":"Demine S","year":"2019","unstructured":"Demine S, Renard P, Arnould T.  Mitochondrial uncoupling: a key controller of biological processes in physiology and diseases. Cells. 2019, 8:795. 10.3390\/cells8080795","journal-title":"Cells"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2010.06.018","article-title":"Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges","volume":"20","author":"Lafor\u00eat P","year":"2010","unstructured":"Lafor\u00eat P, Vianey-Saban C. Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges. Neuromuscul Disord. 2010, 20:693-700. 10.1016\/j.nmd.2010.06.018","journal-title":"Neuromuscul Disord"},{"key":"ref16","article-title":"Multiple acyl-CoA dehydrogenase deficiency","author":"Muraresku IC","year":"2020","unstructured":"Muraresku IC, McCormick EM, Falk MJ. Multiple acyl-CoA dehydrogenase deficiency. GeneReviews\u00ae. Adam MP, Feldman J, Mirzaa GM, et al. (ed): University of Washington, Seattle; 2020."},{"key":"ref17","article-title":"Drug-induced myopathies","author":"Naddaf E","year":"2025","unstructured":"Naddaf E, Bhai S, Dimachkie MM. Drug-induced myopathies. UpToDate. 2025,","journal-title":"UpToDate"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/409840-progressive-weakness-in-adulthood-lipid-storage-myopathy-with-suspected-sertraline-associated-etiology","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:57:06Z","timestamp":1766170626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/409840-progressive-weakness-in-adulthood-lipid-storage-myopathy-with-suspected-sertraline-associated-etiology"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.99645","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,19]]}}}